Revvity Reports Mixed Q2 2026 Results Amid China Business Divestiture
Event summary
- Revvity reported GAAP EPS of $0.48, up from $0.47 YoY, with revenue at $730M (+1.4% YoY).
- Adjusted operating profit margin improved to 28.9% (vs. 26.6% YoY) due to tariff refunds.
- Diagnostics segment grew 12% YoY organically, while Life Sciences declined 3%.
- Company agreed to divest its China Immunodiagnostics business, representing ~6% of 2025 revenue.
- Full-year 2026 guidance: $2.83B-$2.86B revenue (4-5% organic growth), adjusted EPS $5.30-$5.40.
The big picture
Revvity's Q2 results highlight the tension between organic growth challenges in Life Sciences and strong demand in Diagnostics. The China divestiture signals a strategic pivot, potentially freeing capital for higher-growth segments amid broader healthcare sector consolidation trends.
What we're watching
- Segment Strategy
- Whether Revvity can offset Life Sciences declines with Diagnostics growth...
- Divestiture Impact
- How the China Immunodiagnostics exit will affect 2027 financials and focus...
- Margin Sustainability
- The pace at which tariff-related benefits fade without new operational efficiencies...
Related topics